PropertyValue
is ?:annotates of
?:authorAffiliation
  • [\'Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.\', \'Autoimmune Bullous Diseases Research Center, Razi Hospital, Tehran University of Medical Sciences, Tehran, Iran.\', \'Department of Dermatology, Babol University of Medical Sciences, Babol, Iran.\', \'Student Research Committee, School of Medicine, Iran University of Medical Sciences, Tehran, Iran.\', \'Department of Dermatology, Rasool Akram Medical Complex, Iran University of Medical Sciences, Tehran, Iran.\']
?:citedBy
  • -1
?:creator
?:doi
  • 10.1080/08923973.2021.1953063
?:doi
?:hasPublicationType
?:journal
  • Immunopharmacology and immunotoxicology
is ?:pmid of
?:pmid
?:pmid
  • 34287098
?:publication_isRelatedTo_Disease
?:rankingScore_SJR
  • 0.711
?:rankingScore_hIndex
  • 41
is ?:relation_isRelatedTo_publication of
?:title
  • A systematic review on efficacy, safety, and treatment-durability of low-dose rituximab for the treatment of Pemphigus: special focus on COVID-19 pandemic concerns.
?:type
?:year
  • 2021

Metadata

Anon_0  
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://purl.org/net/provenance/ns#DataItem>
<http://www.w3.org/1999/02/22-rdf-syntax-ns#type> <http://www.w3.org/2004/03/trix/rdfg-1/Graph>
<http://xmlns.com/foaf/0.1/primaryTopic> <https://research.tib.eu/covid-19/entity/34287098>
<http://xmlns.com/foaf/0.1/topic> Anon_0
<http://www.ontologydesignpatterns.org/cp/owl/informationrealization.owl#realizes> <https://research.tib.eu/covid-19/data/entity/34287098>
<http://purl.org/net/provenance/ns#createdBy>
Anon_1   (more)
expand all